Laboratory CORP of America Holdings: directors' dealings · United States · SEC (Form 4)

About Laboratory CORP of America Holdings

Laboratory Corp of America Holdings, ticker LH, is listed on the NYSE in the United States and is one of the leading global providers of laboratory services. Headquartered in Burlington, North Carolina, the company traces its roots back to 1971, when it was founded in Burlington and grew from a regional clinical lab business into a diversified diagnostics and drug-development platform. Labcorp’s business model now sits at the intersection of patient care, hospital and health-system laboratory services, and biopharmaceutical R&D support. ([labcorp.com](https://www.labcorp.com/about/corporate-facts?utm_source=openai)) The group reports operations through two core segments. Labcorp Diagnostics covers routine and specialty clinical testing, anatomic pathology, and broad access to patients and providers across the U.S. The company says it operates nearly 2,200 patient service centers and more than 7,000 in-office phlebotomists, giving it one of the largest retail-style access networks in the healthcare diagnostics market. Drug Development provides central laboratory, clinical trial, and broader development support to pharmaceutical and biotechnology customers. This dual structure gives Labcorp exposure to both recurring patient testing and higher-value, research-driven biopharma workflows. ([labcorp.com](https://www.labcorp.com/about/corporate-facts?utm_source=openai)) From a competitive standpoint, Labcorp benefits from scale, a wide test menu, scientific depth, and a large global footprint. The company states that its nearly 71,000 employees serve clients in approximately 100 countries and that it supported more than 85% of the new drugs and therapeutic products approved by the FDA in 2025. That kind of footprint supports strong relationships with hospitals, health systems, physicians, payers, and drug developers, while also reinforcing barriers to entry in specialty diagnostics and central-lab services. ([labcorp.com](https://www.labcorp.com/about/corporate-facts?utm_source=openai)) Recent strategic developments have reinforced Labcorp’s innovation profile. In 2025, the company launched multiple new specialty tests across oncology, women’s health, neurology, and autoimmune disease. It also introduced the first FDA-cleared blood test for Alzheimer’s disease and expanded its precision oncology offering with molecular residual disease and liquid biopsy solutions. On the inorganic side, Labcorp pursued targeted acquisitions of outreach laboratory assets and partnerships with health systems and regional labs, aiming to broaden access to its test menu and strengthen local market penetration. Management’s February 2026 earnings release highlighted full-year 2025 revenue growth, margin expansion, strong free cash flow, and 2026 guidance that points to continued momentum. ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-first-fda-cleared-blood-test-alzheimers-disease?utm_source=openai)) For French-speaking investors in France, Belgium, and Switzerland, LH can be viewed as a healthcare compounder with defensive characteristics and structural growth drivers: aging demographics, rising demand for specialized diagnostics, laboratory consolidation, and continued outsourcing of clinical trial work by pharma companies. The investment case is anchored in recurring testing demand, global scale, and ongoing innovation in precision medicine. ([labcorp.com](https://www.labcorp.com/about/corporate-facts?utm_source=openai))